6
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Viscosity Lowering of Difldnisal Fatty Suppository by Hydrogehated Lecithins

, , , &
Pages 1291-1307 | Published online: 20 Oct 2008
 

Abstract

Diflunisal (Dif), Salicylic Acid Derivative, Is A Nonsteroidal Anti-Inflammatory Drug (Nsaid). Preparation Of Dif Suppositories Which Have A Good Bioavailability Was Attempted. Suppositories Containing Dif (250 Mg, Oral Dose) Were Made By The Fusion Method With Pharmasol B-115 (1050 Mg). However, The Dif Suppository Melt Revealed High Viscosity, And The Finding Was Considered To Be Not Acceptable For Manufacture. Accordingly, The Investigation Was Designed To Select An Optimum Additive Which Is Effective To Lower The Viscosity Of The Suppository Melt. The Viscosity Of The Suppository Melt Was Determined By Utilizing Rotating-Cy1inder Viscometer And Then Bingham Viscosity And Yield Value Were Evaluated. As The Results, Some Lecithins And Magnesium Stearate Were Found To Be Effective To Lower The Viscosity Of Dif Suppository Melts. The Theologically Optimum Formulation Contains Lecinol S-10 (4%) And This Formulation Was Evaluated. In The Evaluation, Physical Properties Such As Melting Point, Hardness, Softening Time, Viscosity Etc., Were Measured By Common Methods. Their Properties Were Satisfactory And Were Practically Stable At 5'c. Dif Itself Was Also Stable In Suppository Melts At 60°C.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.